葡萄糖剥夺的肿瘤微环境激活 AMP 活化蛋白激酶驱动过继转移的 T 辅助 9 细胞衰老
Glucose-deprived tumor microenvironment activates AMP-activated protein kinase to drive adoptively transferred T helper 9 cell senescence.
辅助性T细胞9(Th9)细胞在针对实体瘤的过继细胞治疗(ACT)中显示出前景。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
FRONTIER PAPERS
近 5 年肿瘤细胞治疗领域的研究论文,按发表时间由近到远排列。期刊指标供参考,不代表单项研究的证据强度。
清除检索条件Glucose-deprived tumor microenvironment activates AMP-activated protein kinase to drive adoptively transferred T helper 9 cell senescence.
辅助性T细胞9(Th9)细胞在针对实体瘤的过继细胞治疗(ACT)中显示出前景。
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
12th Immunotherapy of Cancer Conference (ITOC12): A meeting report.
癌症免疫治疗(ITOC)会议是一个领先的国际会议,汇聚了来自世界各地的免疫肿瘤学研究人员和临床医生,以展示和讨论该领域的新兴研究和最新进展。
Defining value criteria for outcomes-based managed entry agreements in CAR-T therapy for relapsed/refractory multiple myeloma: a multi-criteria decisi
在这项结构化的MCDA-informed专家权重评估中,OS和PFS被确定为设计和监测RRMM中CAR-T 疗法基于结果的MEAs的最高优先级价值标准。
Consolidative allogeneic HCT vs. a watch-and-wait approach for B-cell acute lymphoblastic leukemia patients with early loss of B-cell aplasia after CA
Co-expression of non-signaling CARs enhances EGFRvIII-specific CAR T-cell cytotoxicity against head and neck squamous cell carcinoma.
EGFR nsCAR 共表达可提供一种模块化策略,在靶抗原可用性有限的条件下增强 EGFRvIII CAR-T 细胞的细胞毒性。
Dissociation between systemic inflammatory markers and the tumor microenvironment in predicting sentinel lymph node metastasis in cutaneous melanoma.
Next-generation CAR-T therapy for malignant brain tumors: latest updates from the 2026 AACR Annual Meeting.
这些发现支持基于机制的 CAR-T 细胞平台,同时强调持久性、神经毒性、运输、免疫原性和患者选择需要在更大规模的临床研究中验证。
Opposing functions of gut immunomodulatory metabolites on CAR-T therapy.
在一项纳入德国三家中心129例患者的队列中,鸟枪法宏基因组学和靶向质谱分析显示,CAR-T 细胞治疗前短链脂肪酸(尤其是戊酸)水平降低与疾病进展风险增加相关。
MEMBER ACCOUNT
登录成功会直接打开下一页。